Themis Medicare Shareholders Approve ₹430 Cr Related Party Transactions and Warrants Amidst Invalid Promoter Votes

Themis Medicare Limited shareholders have approved material related party transactions totalling ₹430 crore and the issuance of convertible warrants worth ₹45.96 crore. However, the voting process highlighted a governance issue, as a substantial number of promoter votes were invalidated for three resolutions.

Key Shareholder Approvals Granted

Themis Medicare Limited secured shareholder approval for key corporate proposals via a postal ballot that concluded on March 27, 2026. Shareholders overwhelmingly endorsed material related party transactions valued at ₹430 crore for FY 2026-27. These include sales up to ₹250 crore to TDPL/VMIPL, ₹50 crore for GTBL, and ₹130 crore for the transfer of GTBL shares involving Dr. Sachin D. Patel. The company also received approval for the preferential issuance of 4595795 convertible warrants at ₹100 each, totaling approximately ₹45.96 crore, intended for working capital and general corporate needs. A notable issue arose as 2355780 votes from the Promoter and Promoter Group were deemed invalid for three of the four resolutions, citing Regulation 23 of SEBI's Listing Obligations and Disclosure Requirements.

Impact of the Approvals

The approved related party transactions aim to streamline operations and ensure supply chain continuity for essential pharmaceutical intermediates. The warrant issuance, a standard capital-raising method, can strengthen the company's balance sheet and support growth. However, the invalidation of promoter votes introduces scrutiny regarding corporate governance.

Company Background and Context

Themis Medicare Limited is a research-based pharmaceutical firm manufacturing formulations and APIs for domestic and international markets. The company has a history of related party dealings, having previously approved transactions, such as ₹250 crore for formulation sales in FY2025-26. This is not the first time the company has explored warrant issuance; it has previously sought shareholder approval. Notably, Themis Medicare is also contesting a tax demand of approximately ₹13.32 crore from the Income Tax Department for assessment years 2017-18 to 2020-21. Earlier, a proposed amalgamation with Gujarat Themis Biosyn Limited (GTBL) was withdrawn by GTBL's board.

Key Developments Post-Approval

The approved related party transactions are expected to enhance operational efficiency and supply chain reliability for key intermediates. The warrant issuance, pending regulatory approvals, could dilute existing shareholding but will bolster the company's financial resources. The invalidation of promoter votes emphasizes the importance of adhering to SEBI regulations in shareholder dealings. Successful warrant issuance may also pave the way for future capital-raising activities.

Governance Concerns

A primary risk involves the governance implications stemming from the invalidated promoter votes. While all resolutions passed with significant majorities, the disqualification under SEBI regulations could invite further regulatory attention or scrutiny from minority shareholders.

Industry Landscape

Major Indian pharmaceutical companies such as Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Torrent Pharmaceuticals Ltd., and Dr. Reddy's Laboratories Ltd. operate in the same dynamic sector. While these peers also navigate complex regulatory environments and related party transactions, Themis Medicare's current situation highlights specific governance considerations arising from its promoter voting.

Recent Company Metrics

As of March 2026, Themis Medicare's promoter shareholding was reported at 67.11%. As of December 2025, the company reported declining net sales and net losses.

Investor Watchlist

Investors will be tracking the formal allotment process for the convertible warrants to Vividhmargi Investments Private Limited. They will also watch the implementation and financial impact of the approved related party transactions. Further disclosures or actions related to the invalidated promoter votes and SEBI Regulation 23 will be important. The company's ongoing financial performance, including profitability and working capital management, remains a key area of focus.